Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 1010SyNergy, HA1737/16-1)
Association for Frontotemporal Degeneration (-)
National Institutes of Health (R01AG044546, RF1AG053303, RF1AG058501, and U01AG058922)
Fondazione Italiana Sclerosi Multipla (FISM 2017/R/20)
Instituto de Salud Carlos III (-)
H2020 Marie Skłodowska-Curie Actions (752310)
Received: 1 August 2018
Accepted: 4 December 2018
First Online: 10 January 2019
Ethics approval and consent to participate
: The study was approved by the Ludwig-Maximilians Universität München institutional review board (IRB), as well as the IRB of all participating centers in ADNI.
: Not applicable.
: CH collaborates with DENALI Therapeutics and received speakers honoraria from Novartis and Roche. KS collaborates with DENALI. JL reports to receive consulting fees from Aesku, Axon Neuroscience and Ionis Pharmaceuticals, speakers’ fees from Bayer Vital and the Willi Gross and non-financial support from Abbvie, outside the submitted work. CC receives research support from Biogen, EISAI, Alector and Parabon, and is a member of the advisory board of ADx Healthcare. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The remaining authors declare that they have no competing of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.